- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04930159
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SISTER is a prospective, open randomized controlled trial of U.S. Black/African-American people with high-risk endometrial cancer requiring treatment with chemotherapy, radiation, or immunotherapy. We will compare social support interventions of enhanced usual care, weekly group-based support, and 1:1 peer support to determine the most effective option to improve treatment completion and decrease social isolation.
The SISTER study comparators are based on multiple systematic reviews of peer support literature, input from the multi-stakeholder Steering Group of the Endometrial Cancer Action Network for African Americans (ECANA), two focus groups of Black women with EC, and cancer center leadership at selected enrollment sites. The core function of each comparator is to decrease social isolation for women on active treatment. Of the peer support intervention options available, the SISTER study includes the two that have the most data collected among Black women with cancer, have been most efficacious with regard to social isolation9 and treatment completion, and were enthusiastically supported by ECANA patient partners and focus group data.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kemi M Doll, MD, MS
- Phone Number: 206-543-3669
- Email: kdoll@uw.edu
Study Contact Backup
- Name: SISTER team
- Phone Number: 1-844-374-7837
- Email: sisterstudy@uw.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama
-
Principal Investigator:
- Rebecca Arend, MD
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- University of Arkansas for Medical Sciences
-
Principal Investigator:
- Heather Williams, MD
-
Contact:
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Principal Investigator:
- Navya Nair, MD
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- The University of Chicago
-
Principal Investigator:
- Nita Lee, MD, MPH
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Louisiana State University - New Orleans
-
Principal Investigator:
- Tara Castellano, MD
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Recruiting
- Johns Hopkins University
-
Contact:
- SISTER study
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
Principal Investigator:
- Katherine Stewart, MD
-
Columbia, Maryland, United States, 21044
- Recruiting
- Medstar Health Research Institute
-
Principal Investigator:
- Charlotte Gamble, MD MPH
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Weill Cornell Medicine
-
Principal Investigator:
- Eloise Chapman-Davis, MD
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina
-
Principal Investigator:
- Victoria Bae-Jump, MD, PhD
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Fred Hutch/University of Washington Cancer Consortium
-
Principal Investigator:
- Kemi M Doll, MD, MSCR
-
Contact:
- SISTER team
- Phone Number: 844-374-7837
- Email: sisterstudy@uw.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult 18 years of age or older; and
- Self-identify as Black/African American
Presenting with high-risk EC established by anatomic pathology as tumor stage and grade classification by the following:
- Pathology documentation from any hospital/clinic/medical center, and
- FIGO Stage 1A with Grade 2, Grade 3, or Grade 4 of any histology type or
- FIGO Stage 1A with non-endometrioid (carcinosarcoma, serous, clear cell, undifferentiated or mixed) histology
- FIGO Stage 1B, 2, 3, or 4 of any grade or histology
- Recurrent endometrial cancer of any stage or grade
- Documented provider recommendation and patient plan to initiate adjuvant therapy with chemotherapy, radiation, and/or immunotherapy.
Exclusion Criteria:
Participants must not have any of the following exclusion criteria:
- Newly diagnosis of FIGO Stage IA Grade 1 endometrioid adenocarcinoma
- Previous history of other cancer diagnosis requiring chemotherapy, radiation therapy, or immunotherapy within the past 12 months;
- Incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline/screening;
- Contraindication to all non-surgical therapy available for endometrial cancer (i.e., chemotherapy, radiation, and immunotherapy contraindicated);
- Enrollment into hospice prior to randomization
- Unable to provide written informed consent in English;
- Unable to be contacted for research surveys;
- Recent hospitalization for psychiatric illness in the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Enhanced usual care
Written materials in an appealing package.
|
|
Active Comparator: Facilitated group support
Weekly group gatherings.
|
Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine.
Each group will cycle through the same order of topics.
|
Active Comparator: 1:1 Peer Support
Individual peer support calls.
|
1:1 peer support via telephone or video either during or near a treatment visit.
Call content will be focused on social support and driven by the needs of the participant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment completion (relative dose)
Time Frame: 6 months
|
Relative dose is the ratio of actual-to-expected total dose of treatment received.
The calculation of expected total dose will be made from the baseline treatment recommendation data collected at enrollment.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-reported social isolation (SPS-24)
Time Frame: 6 months
|
The Social Provisions Scale (SPS) is one of the most frequently used scales on social support, and is validated to measure the components of social support that directly impact health outcomes: attachment, social integration, reassurance of worth, reliable alliance, guidance, and opportunity for nurturance.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kemi M Doll, MD, MS, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Disease Attributes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Recurrence
- Endometrial Neoplasms
Other Study ID Numbers
- STUDY00012990
- RG1121627 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- NCI-2021-12773 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Masonic Cancer Center, University of MinnesotaCompletedCervical Cancer | Ovarian Cancer | Uterine Endometrial CancerUnited States
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
Clinical Trials on Facilitated group support
-
Elizabeth Glaser Pediatric AIDS FoundationMinistry of Health and Child Welfare, Zimbabwe; The Children's Investment Fund...CompletedHIV-infection/Aids
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteCompleted
-
University of Wisconsin, MadisonWisconsin Partnership ProgramRecruiting
-
University of AlbertaRecruiting
-
Johns Hopkins UniversityNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Johns Hopkins UniversityCompleted
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingAdvance Care PlanningUnited States
-
National Yang Ming UniversityCompleted
-
Vanderbilt University Medical CenterCompletedEducation, Medical | Care, Palliative | Education, Medical, Graduate | Medicine, PalliativeUnited States